GPGrossPatternRESEARCH SYSTEM
SEC CHECK OPERATIONAL
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

GH · Mar 31, 2025

Guardant Health, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration

State dimensions

Filing0001576280-25-000136General Corporate
Debt relative to revenueRAWCurrent state valid · history insufficient
Evidence method

Level · gp.fundamentals.debt_to_revenue

548.65% · OPTIONAL · NOT_ENOUGH_HISTORY

Capex intensity5thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.capex_revenue_ratio

2.19% · OPTIONAL · VALID

Operating cash generation70thOwn-history percentile · N=20
Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

-30.81% · OPTIONAL · VALID

Revenue growth19thOwn-history percentile · N=16
Evidence method

Yoy · gp.fundamentals.revenue

20.76% · CORE · VALID

Inventory pressure75thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

37.97% · OPTIONAL · VALID

Gross marginRAWCurrent state valid · history insufficient
Evidence method

Level · gp.fundamentals.gross_margin

63.28% · CORE · NOT_ENOUGH_HISTORY

Operating margin95thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.operating_margin

-54.57% · CORE · VALID

R&D intensity0thOwn-history percentile · N=20
Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

43.51% · OPTIONAL · VALID

SBC intensity40thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

18.56% · OPTIONAL · VALID

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History22 statesSelf-history eligible
Sep 30, 20210/7 normalizedLevel 3Dec 31, 20210/7 normalizedLevel 3Mar 31, 20226/7 normalizedLevel 3Jun 30, 20226/7 normalizedLevel 3Sep 30, 20226/7 normalizedLevel 3Dec 31, 20226/7 normalizedLevel 3Mar 31, 20237/7 normalizedLevel 3Jun 30, 20237/7 normalizedLevel 3Sep 30, 20237/7 normalizedLevel 3Dec 31, 20237/7 normalizedLevel 3Mar 31, 20247/7 normalizedLevel 3Jun 30, 20247/7 normalizedLevel 3Sep 30, 20247/7 normalizedLevel 3Dec 31, 20247/7 normalizedLevel 3Mar 31, 20257/9 normalizedLevel 3Jun 30, 20257/9 normalizedLevel 3Sep 30, 20257/9 normalizedLevel 3Dec 31, 20257/9 normalizedLevel 3Mar 31, 20267/9 normalizedLevel 3Jun 30, 20267/9 normalizedLevel 4
Period transition

What moved in the state?

Capex Intensity Decreased
Previous
4.75%
Current
2.19%
Delta
-2.56%
Cash Generation Increased
Previous
-32.46%
Current
-30.81%
Delta
1.65%
Growth Decreased
Previous
31.04%
Current
20.76%
Delta
-10.28%
Inventory Pressure Increased
Previous
9.62%
Current
37.97%
Delta
28.35%
Profitability Increased
Previous
-60.02%
Current
-54.57%
Delta
5.45%
R And D Intensity Decreased
Previous
47.06%
Current
43.51%
Delta
-3.55%
Sbc Intensity Decreased
Previous
19.00%
Current
18.56%
Delta
-0.44%
Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.
Research Graph

Related governed research

Transitioned To · GH Fundamental State →Has State · Guardant Health, Inc. →Transitioned To · GH Fundamental State →Transitioned To · GH CAPEX_INTENSITY_DECREASED →Transitioned To · GH CASH_GENERATION_INCREASED →Transitioned To · GH GROWTH_DECREASED →Transitioned To · GH INVENTORY_PRESSURE_INCREASED →Transitioned To · GH PROFITABILITY_INCREASED →Transitioned To · GH R_AND_D_INTENSITY_DECREASED →Transitioned To · GH SBC_INTENSITY_DECREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.